Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168915 · ClinicalTrials.gov registry record · Phase 1
A Study of V118E in Healthy Participants (V118E-003)
A Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
- 4
- Study locations
NCT07168915: Recruiting Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.
NCT07168915 is a Phase 1 study of Healthy that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 126 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07168915, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
- 4
- Study locations
Study Summary
Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria. PREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria. The goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.
Primary Outcome
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, which occurs during the course of the study. A solicited AE is a predefined event that participants are specifically asked about and record on their vaccine report card (VRC). Solicited injection-site AEs include redness, swelling, and
Conditions Studied
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL V118E
- BIOLOGICAL PREVNAR 20™
Study Locations (4)
Florida
- Velocity Clinical Research, Hallandale Beach ( Site 0003) - Hallandale
- QPS-MRA, LLC-Early Phase ( Site 0002) - South Miami
Missouri
- Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0004) - Springfield
Texas
- University of Texas Medical Branch ( Site 0001) - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2025-10-08 |
| Est. Completion | 2027-11-12 |
| Phase | Phase 1 |
What NCT07168915 shows while recruiting
NCT07168915 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Saline is the first listed.
NCT07168915 reports a single indexed study location in Florida, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT07168915 about?
NCT07168915 is a clinical study titled "A Study of V118E in Healthy Participants (V118E-003)". Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infectio...
What is the current status of trial NCT07168915?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2025-10-08. Estimated completion is 2027-11-12.
What conditions does trial NCT07168915 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT07168915?
The interventions under investigation include: Saline (BIOLOGICAL), V118E (BIOLOGICAL), PREVNAR 20™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT07168915?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07168915 being conducted?
This trial has 4 study locations across Florida, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07168915's enrollment target sits among peer trials
126 175th of 1090 higher than 916 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of TIX100 in Healthy Subjects
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI